Clinical trials: Malignant Neoplasm of Prostate
mCRPC
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
This trial is designed to evaluate the safety and efficacy of anti-IGF-1R mAb in combination with anti-PD-1 mAb in patients with mCRPC.
- Trial name
- NCT06866548
- Testing
- anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab)
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Shanghai Changzheng Hospital
Local Recurrence of Malignant Tumor of Prostate, Radiotherapy
Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy
The goal of this clinical study is to evaluate the toxicity and efficacy of re-irradiation using focal stereotactic body radiotherapy (SBRT) in patients with local recurrence of prostate cancer after definitive or post-operative…
- Trial name
- PROSTARE (NCT06201078)
- Testing
- Stereotactic Body Radiotherapy
- Where
- Poland
- Volunteers
- 55 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Prostatic Neoplasms, Neoplasm Recurrence, Local
Gene Therapy for Prostate Cancer That Returns After Radiation Therapy
The purpose of this research study is to test a new treatment for prostate cancer. We have been exploring the use of cytokine (immune stimulating) gene therapy by directly injecting a virus which produces a cytokine called…
- Trial name
- NCT00110526
- Testing
- Ad.hIL-12
- Sponsor
- Simon Hall
Prostate Cancer
Open Label Prostate Cancer Study
The main purpose of the study is to investigate the safety and tolerability of AZD3514 when given orally to patients with castration-resistant prostate cancer (CRPC)
- Trial name
- NCT01162395
- Testing
- AZD3514
- Where
- 5 sites in United States, Netherlands and 1 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Lymphoedema, Breast Cancer
Spa Therapy for Upper or Lower Limb Lymphoedema
THERMOEDEME is a comparative, controlled, randomized, multicenter and simple blinded (investigator) trial. The aim of this study is to evaluate effects of spa therapy in phlebology with a therapeutic education program in daily…
- Conditions
- Lymphoedema, Breast Cancer, Malignant Disease, Gynaecological Cancer
- Trial name
- THERMOEDEME (NCT03580109)
- Testing
- Immediate spa treatment, Late spa treatment
- Where
- 13 sites in France
- Volunteers
- 160 people
- Sponsor
- Association Francaise pour la Recherche Thermale
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Castration-Resistant Prostatic Cancer, Metastatic Disease
Safety and Targeting of Anti-hk2 Antibody in mCRPC
This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC. This imaging study will be conducted to confirm the safety and estimate the mass amount of antibody h11B6, and confirm in vivo…
- Trial name
- NCT04116164
- Testing
- 111In-DOTA-h11B6
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- SpectronRX
Prostate Cancer, Prostate Cancer Metastatic
MSG Use With 18F-DCFPyL PET/CT Imaging
18F-DCFPyL is an agent that binds to prostate specific membrane antigen (PSMA). Due to high levels of PSMA in prostate cancer, treatments targeting PSMA have been developed to deliver therapy to these specific target cells.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostatic Neoplasm
- Trial name
- NCT03693742
- Testing
- 18F-DCFPyL PET/CT scan, MSG drink
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer.
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03649841
- Testing
- Antiandrogen Therapy, Abiraterone Acetate, Prednisone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
Urological Malignancies, Prostate Cancer
Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
Genitourinary malignancies such as prostate cancer, renal cell cancer, and bladder cancer in Korean population have been increased due to the aged population and the westernized lifestyles.
- Conditions
- Urological Malignancies, Prostate Cancer, Renal Cell Cancer, Bladder Cancer
- Trial name
- NCT04625556
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Yonsei University
Prostate Cancer, Metastatic (Spread to Other Areas of the Body)
BKM120 in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the effects of the study drug, BKM120. The study drug, BKM120, is an inhibitor of a protein called phosphatidyl inositol-3-kinase (PI3K).
- Trial name
- NCT01385293
- Testing
- BKM120
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Andrew J. Armstrong, MD
Prostate Cancer
Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)
The goal of this clinical research study is to learn if treatment with standard systemic therapy (androgen deprivation therapy or bilateral orchiectomy) in combination with surgery or radiation therapy is more effective at…
- Trial name
- NCT01751438
- Testing
- Best Systemic Therapy (BST), Best Systemic Therapy (BST) + Surgery or Radiation Therapy, Questionnaires
- Where
- 4 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer (EPIDROP)
The use of liquid biopsy could be the key for precision medicine. Circulating tumor cells (CTCs) are the most studied circulating biomarkers used to assess the metastatic process and they have shown their clinical validity and…
- Trial name
- EPIDROP (NCT04581109)
- Testing
- Blood sample
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Prostate Cancer, Prostatic Neoplasm
68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical
This is a preliminary evaluation of a radiotracer's biodistribution in human subjects. It is a prospective, single-centre, open-label, single group assignment interventional study.
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Disease, Urogenital Neoplasms
- Trial name
- NCT04831307
- Testing
- [68Ga]Ga-HTK03149 PET/CT
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Neoplasm of Breast (Disorder), Carcinoma of Prostate (Disorder)
An Observational Prospective Cohort Study Using an Actigraphy Device.
This study focuses on whether or not physical activity and sleep quality correlate with the health of prostate and breast cancer patients.
- Trial name
- NCT03475433
- Testing
- Actigraphy device
- Where
- 2 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- Taipei Medical University
Prostate Cancer, Neoplasm Metastasis
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Multicenter study in which patients with metastatic hormone refractory prostate cancer (HRPC), who have not had previous chemotherapy or immunotherapy treatments, received MDX-010 every 3 weeks for 4 doses (12 weeks total…
- Trial name
- NCT00323882
- Testing
- MDX-010
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the standard of care and be enrolled in the study for 12 months post-op.
- Conditions
- Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy
- Trial name
- NCT07234968
- Testing
- Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Thomas Jefferson University